Cargando…

Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population

INTRODUCTION: Real-world pharmacoutilization analysis of biological drugs in psoriatic arthritis (PsA) patients with the aim to evaluate biologic treatment patterns and pharmacoutilization among patients with PsA in Italy. METHODS: A retrospective study was conducted using administrative databases o...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Valentina, Losi, Serena, Filippi, Erica, Mezzetti, Maurizio, Dovizio, Melania, Sangiorgi, Diego, Degli Esposti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127009/
https://www.ncbi.nlm.nih.gov/pubmed/35316515
http://dx.doi.org/10.1007/s40744-022-00440-1
_version_ 1784712252988850176
author Perrone, Valentina
Losi, Serena
Filippi, Erica
Mezzetti, Maurizio
Dovizio, Melania
Sangiorgi, Diego
Degli Esposti, Luca
author_facet Perrone, Valentina
Losi, Serena
Filippi, Erica
Mezzetti, Maurizio
Dovizio, Melania
Sangiorgi, Diego
Degli Esposti, Luca
author_sort Perrone, Valentina
collection PubMed
description INTRODUCTION: Real-world pharmacoutilization analysis of biological drugs in psoriatic arthritis (PsA) patients with the aim to evaluate biologic treatment patterns and pharmacoutilization among patients with PsA in Italy. METHODS: A retrospective study was conducted using administrative databases of Italian Entities. PsA patients were included and diagnosed by hospitalization and/or an active exemption code. Two analyses were performed: a cross-sectional for treatment patterns in patients enrolled among 2017–2020, and a longitudinal study during 2015 to investigate the pharmacoutilization, in terms of persistence and monthly maintenance dosage of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Patients with or without b/tsDMARDs prescriptions before inclusion were defined as bioexperienced or naïve, respectively. An analysis on ixekizumab-treated patients (IXE patients) from the 2017-to study ending was performed. RESULTS: PsA was diagnosed in 24,786 (2017), 27,221 (2018), 28,889 (2019), and 29,292 (2020) patients. Across 2017–2020, 31.1–40.5% of PsA patients were untreated with systemic medications, and 16.4–18.8% were under biological therapies. Among b/tsDMARD-treated patients, decreasing use of TNF-inhibitors (77.6–57.1%) and increasing IL-inhibitors (19.6–33.2%) was found across 2017–2020, respectively. Persistence to TNF-inhibitors and IL inhibitors as first-line ranged, respectively, 74.9–83.0% and 73.0–84.6%; specifically, 73.1–76.9% and 73.0–83.8% among bio-naïve, 83.3–90.0%, and 87.0% among bio-experienced. Among IXE-patients (N = 178), 55.6% were bio-naïve, while 21.9% previously used secukinumab, 12.9% adalimumab, 10.1% etanercept. During a 1-year follow-up, 6.8% of IXE patients switched therapy. CONCLUSIONS: This real-world study of PsA pharmacoutilization in Italy showed that more than one-third of patients were systemically untreated, and almost 20% were receiving biological medications. Among biological users, increasing use of IL-inhibitors and a decrease in TNF-inhibitors prescriptions over the years were found. A rather-high extent of persistency in treatment was observed. A focused analysis on IXE patients revealed over half of them to be bio-naïve, while around one-fourth were bio-experienced to IL inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-022-00440-1.
format Online
Article
Text
id pubmed-9127009
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-91270092022-05-25 Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population Perrone, Valentina Losi, Serena Filippi, Erica Mezzetti, Maurizio Dovizio, Melania Sangiorgi, Diego Degli Esposti, Luca Rheumatol Ther Original Research INTRODUCTION: Real-world pharmacoutilization analysis of biological drugs in psoriatic arthritis (PsA) patients with the aim to evaluate biologic treatment patterns and pharmacoutilization among patients with PsA in Italy. METHODS: A retrospective study was conducted using administrative databases of Italian Entities. PsA patients were included and diagnosed by hospitalization and/or an active exemption code. Two analyses were performed: a cross-sectional for treatment patterns in patients enrolled among 2017–2020, and a longitudinal study during 2015 to investigate the pharmacoutilization, in terms of persistence and monthly maintenance dosage of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Patients with or without b/tsDMARDs prescriptions before inclusion were defined as bioexperienced or naïve, respectively. An analysis on ixekizumab-treated patients (IXE patients) from the 2017-to study ending was performed. RESULTS: PsA was diagnosed in 24,786 (2017), 27,221 (2018), 28,889 (2019), and 29,292 (2020) patients. Across 2017–2020, 31.1–40.5% of PsA patients were untreated with systemic medications, and 16.4–18.8% were under biological therapies. Among b/tsDMARD-treated patients, decreasing use of TNF-inhibitors (77.6–57.1%) and increasing IL-inhibitors (19.6–33.2%) was found across 2017–2020, respectively. Persistence to TNF-inhibitors and IL inhibitors as first-line ranged, respectively, 74.9–83.0% and 73.0–84.6%; specifically, 73.1–76.9% and 73.0–83.8% among bio-naïve, 83.3–90.0%, and 87.0% among bio-experienced. Among IXE-patients (N = 178), 55.6% were bio-naïve, while 21.9% previously used secukinumab, 12.9% adalimumab, 10.1% etanercept. During a 1-year follow-up, 6.8% of IXE patients switched therapy. CONCLUSIONS: This real-world study of PsA pharmacoutilization in Italy showed that more than one-third of patients were systemically untreated, and almost 20% were receiving biological medications. Among biological users, increasing use of IL-inhibitors and a decrease in TNF-inhibitors prescriptions over the years were found. A rather-high extent of persistency in treatment was observed. A focused analysis on IXE patients revealed over half of them to be bio-naïve, while around one-fourth were bio-experienced to IL inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-022-00440-1. Springer Healthcare 2022-03-22 /pmc/articles/PMC9127009/ /pubmed/35316515 http://dx.doi.org/10.1007/s40744-022-00440-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Perrone, Valentina
Losi, Serena
Filippi, Erica
Mezzetti, Maurizio
Dovizio, Melania
Sangiorgi, Diego
Degli Esposti, Luca
Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
title Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
title_full Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
title_fullStr Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
title_full_unstemmed Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
title_short Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
title_sort analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an italian population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127009/
https://www.ncbi.nlm.nih.gov/pubmed/35316515
http://dx.doi.org/10.1007/s40744-022-00440-1
work_keys_str_mv AT perronevalentina analysisofthepharmacoutilizationofbiologicaldrugsinpsoriaticarthritispatientsarealworldretrospectivestudyamonganitalianpopulation
AT losiserena analysisofthepharmacoutilizationofbiologicaldrugsinpsoriaticarthritispatientsarealworldretrospectivestudyamonganitalianpopulation
AT filippierica analysisofthepharmacoutilizationofbiologicaldrugsinpsoriaticarthritispatientsarealworldretrospectivestudyamonganitalianpopulation
AT mezzettimaurizio analysisofthepharmacoutilizationofbiologicaldrugsinpsoriaticarthritispatientsarealworldretrospectivestudyamonganitalianpopulation
AT doviziomelania analysisofthepharmacoutilizationofbiologicaldrugsinpsoriaticarthritispatientsarealworldretrospectivestudyamonganitalianpopulation
AT sangiorgidiego analysisofthepharmacoutilizationofbiologicaldrugsinpsoriaticarthritispatientsarealworldretrospectivestudyamonganitalianpopulation
AT degliespostiluca analysisofthepharmacoutilizationofbiologicaldrugsinpsoriaticarthritispatientsarealworldretrospectivestudyamonganitalianpopulation